(paliperidone palmitate 6-month)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA HAFYERA® (paliperidone palmitate 6-month)
Medical Information
Slide Deck: A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients with Schizophrenia
Last Updated: 10/03/2024
SUMMARY
The slide deck titled “A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients with Schizophrenia” is being provided to you in response to your unsolicited request.
INVEGA HAFYERA in ADULT PATIENTS WITH SCHIZOPHRENIa SlidE Deck
These slides are not intended as an endorsement or promotion of any usage not contained in the INVEGA HAFYERA Full Prescribing Information.1
An electronic copy of the slide deck may be accessed by clicking the hyperlink provided below. The deck is provided as a locked file and the content is not intended for modification.
References
| 1 | INVEGA HAFYERA (paliperidone palmitate) [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+HAFYERA-pi.pdf. |